{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:53:58Z","timestamp":1788872038243,"version":"build-2803163510"},"reference-count":16,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000097","name":"National Center for Research Resources (NCCR)","doi-asserted-by":"crossref","award":["1UL1RR024128-0"],"award-info":[{"award-number":["1UL1RR024128-0"]}],"id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NIH Roadmap for Medical Research"},{"name":"Genzyme Corporation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.ymgme.2011.07.004","type":"journal-article","created":{"date-parts":[[2011,7,21]],"date-time":"2011-07-21T13:12:02Z","timestamp":1311253922000},"page":"118-122","source":"Crossref","is-referenced-by-count":30,"title":["An individually, modified approach to desensitize infants and young children with Pompe disease, and significant reactions to alglucosidase alfa infusions"],"prefix":"10.1016","volume":"104","author":[{"given":"Areeg H.","family":"El-Gharbawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Mackey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"DeArmey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Westby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry G.","family":"Grinnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Malovrh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Conway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya S.","family":"Kishnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2011.07.004_bb0005","series-title":"The Metabolic & Molecular Bases of Inherited Disease","first-page":"3389","article-title":"Glycogen storage disease type II: Acid alpha-glucosidase (acid maltase) deficiency","author":"Hirschhorn","year":"2001"},{"key":"10.1016\/j.ymgme.2011.07.004_bb0015","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2011.07.004_bb0020","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2011.07.004_bb0025","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","article-title":"Early treatment with alglucosidase alfa prolongs long term survival of infants with Pompe disease","volume":"66","author":"Kishnani","year":"2009","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgme.2011.07.004_bb0030","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ymgme.2006.09.003","article-title":"The long-term international safety experience of imiglucerase therapy for Gaucher disease","volume":"90","author":"Starzyk","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2011.07.004_bb0035","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"Wilcox","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2011.07.004_bb0040","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","article-title":"Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-l-iduronidase (laronidase)","volume":"144","author":"Wraith","year":"2004","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2011.07.004_bb0045","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1634\/theoncologist.12-5-601","article-title":"Management and preparedness for infusion and hypersensitivity reactions","volume":"12","author":"Lenz","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.ymgme.2011.07.004_bb0050","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.iac.2006.02.004","article-title":"IgE-facilitated antigen presentation: role in allergy and the influence of allergen immunotherapy","volume":"26","author":"Wilcock","year":"2006","journal-title":"Immunol. Allergy Clin. North Am."},{"issue":"2","key":"10.1016\/j.ymgme.2011.07.004_bb0055","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ymgme.2011.02.018","article-title":"Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase","volume":"103","author":"Burton","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2011.07.004_bb0060","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/GIM.0b013e318170f868","article-title":"Successful reinstitution of agalsidase beta therapy in Fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme","volume":"10","author":"Bodensteiner","year":"2008","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2011.07.004_bb0065","doi-asserted-by":"crossref","first-page":"e714","DOI":"10.1542\/peds.2007-0665","article-title":"Successful management of difficult infusion-associated reactions in a young patient with mucopolysaccharidosis type VI receiving recombinant human arylsulfatase B","volume":"121","author":"Kim","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2011.07.004_bb0070","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jpeds.2009.05.033","article-title":"Effective desensitization to imiglucerase in a patient with type I Gaucher disease","volume":"155","author":"Peroni","year":"2009","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2011.07.004_bb0075","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ymgme.2009.07.001","article-title":"Desensitization of an adult patient with Pompe disease and a history of anaphylaxis to Alglucosidase alpha","volume":"98","author":"Lipinski","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2011.07.004_bb0080","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1398-9995.2010.02441.x","article-title":"General considerations on rapid desensitization for drug hypersensitivity\u2014a consensus statement","volume":"65","author":"Cernadas","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.ymgme.2011.07.004_bb0085","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jaci.2008.02.044","article-title":"Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases","volume":"122","author":"Castells","year":"2008","journal-title":"J. Allergy Clin. Immunol."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719211002174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719211002174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T19:36:53Z","timestamp":1588793813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719211002174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":16,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S1096719211002174"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2011.07.004","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}